A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a …
G Frasci, G Nicolella, P Comella, I Carreca… - British journal of …, 2001 - nature.com
The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-
topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients …
topotecan (CPT) weekly administration with G-CSF support in chemo-naive SCLC patients …
Combined-modality therapy for limited-stage small cell lung cancer
WJ Curran Jr - Seminars in oncology, 2001 - Elsevier
While the International Union Against Cancer system can be used in staging small cell lung
cancer (SCLC) patients, the staging distinction of “extensive stage” versus “limited stage” is …
cancer (SCLC) patients, the staging distinction of “extensive stage” versus “limited stage” is …
Treatment of relapsed small cell lung cancer
PE Postmus, EF Smit - Seminars in oncology, 2001 - Elsevier
Small cell lung cancer is a frequently relapsing tumor despite a high rate of response after
first-line chemotherapy. For these patients, treatment at relapse depends on the response to …
first-line chemotherapy. For these patients, treatment at relapse depends on the response to …
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer
EE Vokes, GS Gordon, CM Rudin, AM Mauer… - Investigational new …, 2001 - Springer
In a previous phase II trial of thesynthetic topoisomerase I inhibitor, 9-aminocamptothecin (9-
AC), given as a72-h infusion, we identified modestsingle agent activity of 9% in patientswith …
AC), given as a72-h infusion, we identified modestsingle agent activity of 9% in patientswith …
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer
M Boucaud, F Pinguet, S Poujol, G Romieu… - European Journal of …, 2001 - Elsevier
The comparative saliva/plasma pharmacokinetics of topotecan were investigated in 13
patients with metastatic epithelial ovarian cancer receiving topotecan (30-min intravenous …
patients with metastatic epithelial ovarian cancer receiving topotecan (30-min intravenous …
Therapy of limited stage small cell lung cancer
WJ Curran Jr - Thoracic Oncology, 2001 - Springer
Bronchogenic carcinoma is divided into two distinct entities, small cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC) and these categories have distinguishing clinical …
and non-small cell lung cancer (NSCLC) and these categories have distinguishing clinical …
A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer
P O'Neill, PI Clark, D Smith, E Marshall, K Hannigan… - Oncology, 2001 - karger.com
A phase I dose-escalation study was undertaken to determine the maximum tolerated dose
of the intravenous combination of topotecan and etoposide in previously untreated patients …
of the intravenous combination of topotecan and etoposide in previously untreated patients …
Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy
JR Eckardt - Oncology, 2001 - karger.com
The single-agent activity of intravenous (iv) topotecan has been established in small-cell
lung cancer (SCLC), with overall tumor responses of 39% in previously untreated patients …
lung cancer (SCLC), with overall tumor responses of 39% in previously untreated patients …